Professor of Medicine, Pediatrics, Microbiology and Immunology
Weill Cornell Medicine and NYPH
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Dr. Thomas Walsh serves as Professor of Medicine, Pediatrics, Microbiology & Immunology, Founding Director of the Transplantation-Oncology Infectious Diseases Program of Weill Cornell University Medical Center. Following graduation from Johns Hopkins University School of Medicine, he trained over 10 post-doctoral years in infectious diseases, antimicrobial pharmacology, medical mycology, immunology, and oncology at Johns Hopkins University, University of Maryland, and the National Cancer Institute with the objective of becoming a physician-scientist in infections in immunocompromised patients. He is board-certified in Medicine, Infectious Diseases, and Oncology. During his 23 years at the National Cancer Institute, Bethesda, MD, Dr. Walsh became Chief of the Immunocompromised Host Section in the Pediatric Oncology Branch, where he directed a combined laboratory and clinical translational research program dedicated to immunopharmacology, molecular detection, and pharmacotherapeutics of invasive fungal and MDR bacterial infections in pediatric and adult patients with cancer and hematopoietic stem cell transplantation. Dr. Walsh was then recruited to establish the Weill Cornell Medicine Transplantation-Oncology Infectious Diseases Program, where he established the Patient Care Service, Translational Research Laboratory, Clinical Research Unit, and an international mentoring and training program for studying infections in immunocompromised patients. Finally, in addition to his devoted institutional patient care, Dr. Walsh has extended his expertise throughout the nation and worldwide to the care of numerous more than 1,000 pediatric and adult patients with life-threatening infections. The stories of some of these patients are expressed in letters of gratitude at https://missionfromtheheart.org/. During the past 32 years, Dr. Walsh has mentored more than 200 trainees from 39 different countries. In response to the global public health crisis of COVID-19, he and his colleagues at Weill Cornell Medicine have expanded their clinical research and laboratory investigations to develop new initiatives for understanding the epidemiology, pathogenesis, and treatment of this life-threatening disease in immunocompromised patients.
